Compare IPCA Labs with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs GSK PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS GSK PHARMA IPCA LABS/
GSK PHARMA
 
P/E (TTM) x 23.1 52.1 44.2% View Chart
P/BV x 4.5 11.0 40.8% View Chart
Dividend Yield % 0.1 1.4 7.3%  

Financials

 IPCA LABS   GSK PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
GSK PHARMA
Mar-19
IPCA LABS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6953,595 19.3%   
Low Rs4001,253 31.9%   
Sales per share (Unadj.) Rs260.2184.7 140.9%  
Earnings per share (Unadj.) Rs19.026.3 72.2%  
Cash flow per share (Unadj.) Rs33.129.2 113.3%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.8 22.1%  
Book value per share (Unadj.) Rs213.0126.3 168.7%  
Shares outstanding (eoy) m126.20169.40 74.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.113.1 16.0%   
Avg P/E ratio x28.992.2 31.3%  
P/CF ratio (eoy) x16.683.1 19.9%  
Price / Book Value ratio x2.619.2 13.4%  
Dividend payout %5.376.1 6.9%   
Avg Mkt Cap Rs m69,120410,626 16.8%   
No. of employees `00013.35.0 267.2%   
Total wages/salary Rs m7,3595,372 137.0%   
Avg. sales/employee Rs Th2,477.46,306.7 39.3%   
Avg. wages/employee Rs Th555.21,083.1 51.3%   
Avg. net profit/employee Rs Th180.6898.0 20.1%   
INCOME DATA
Net Sales Rs m32,83631,281 105.0%  
Other income Rs m4181,023 40.9%   
Total revenues Rs m33,25432,304 102.9%   
Gross profit Rs m4,5056,009 75.0%  
Depreciation Rs m1,777486 365.7%   
Interest Rs m2406 4,003.3%   
Profit before tax Rs m2,9056,540 44.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m5112,373 21.5%   
Profit after tax Rs m2,3944,454 53.8%  
Gross profit margin %13.719.2 71.4%  
Effective tax rate %17.636.3 48.5%   
Net profit margin %7.314.2 51.2%  
BALANCE SHEET DATA
Current assets Rs m19,45520,061 97.0%   
Current liabilities Rs m10,07614,543 69.3%   
Net working cap to sales %28.617.6 161.9%  
Current ratio x1.91.4 140.0%  
Inventory Days Days9857 172.4%  
Debtors Days Days6714 476.1%  
Net fixed assets Rs m20,26014,343 141.3%   
Share capital Rs m2521,694 14.9%   
"Free" reserves Rs m26,63319,704 135.2%   
Net worth Rs m26,88621,398 125.6%   
Long term debt Rs m2,3402 117,005.0%   
Total assets Rs m41,17339,113 105.3%  
Interest coverage x13.11,091.0 1.2%   
Debt to equity ratio x0.10 93,124.1%  
Sales to assets ratio x0.80.8 99.7%   
Return on assets %6.411.4 56.1%  
Return on equity %8.920.8 42.8%  
Return on capital %10.831.9 33.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,642534 2,929.2%   
Fx outflow Rs m4,8847,091 68.9%   
Net fx Rs m10,759-6,557 -164.1%   
CASH FLOW
From Operations Rs m3,4113,994 85.4%  
From Investments Rs m-1,354-1,433 94.5%  
From Financial Activity Rs m-1,304-3,584 36.4%  
Net Cashflow Rs m753-1,023 -73.6%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 11.4 10.2 111.8%  
FIIs % 25.3 23.8 106.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 102,036 36.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SUN PHARMA  PFIZER  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS